Hematopoietic Neoplasm/Leukemia - Acute Myeloid Leukemia
NCT00085124
Clinical Trial Information
Trial Number: NCT00085124 (ClinicalTrials.gov)
Disease Type:
- Hematopoietic Neoplasm/Leukemia - Acute Myeloid Leukemia
Trial Title:
A Phase III Study of Daunorubicin and Cytarabine +/- G3139 (Genasense, Oblimersen Sodium, NSC #683428, IND #58842), a BCL2 Antisense Oligodeoxynucleotide, in Previously Untreated Patients With Acute Myeloid Leukemia (AML) ≥ 60 Years
Study ID:
CALGB-10201
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
NCT00046930
Clinical Trial Information
Trial Number: NCT00046930 (ClinicalTrials.gov)
Disease Type:
- Hematopoietic Neoplasm/Leukemia - Acute Myeloid Leukemia
- Hematopoietic Neoplasm/Leukemia - Myelodysplastic Syndrome
Trial Title:
A Randomized, Placebo-Controlled, Double Blind, Trial of the Administration of the MDR Modulator, Zosuquidar Trihydrochloride (LY335979), During Conventional Induction and Post-Remission Therapy in Patients Greater Than 60 Years of Age With Newly Diagnosed Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts in Transformation or High-Risk Refractory Anemia With Excess Blasts
Study ID:
E3999
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
NCT00093470
Clinical Trial Information
Trial Number: NCT00093470 (ClinicalTrials.gov)
Disease Type:
- Hematopoietic Neoplasm/Leukemia - Acute Myeloid Leukemia
Trial Title:
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Study ID:
E2902
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT00093470-D3 | There are three submissions for PMID 34773794. This dataset, NCT00093470-D3, contains toxicity data reported during the first three cycles of treatment or the first three months post registration. Dataset NCT00093470-D1 contains baseline, treatment, and efficacy data. Dataset NCT00093470-D2 contains toxicity data reported on study. |
| NCT00093470-D2 | There are three submissions for PMID 34773794. This dataset, NCT00093470-D2 contains toxicity data reported on study. Dataset NCT00093470-D1 contains baseline, treatment, and efficacy data. Dataset NCT00093470-D3 contains toxicity data reported during the first three cycles of treatment or the first three months post registration. |
| NCT00093470-D1 | There are three submissions for PMID 34773794. This dataset, NCT00093470-D1, contains baseline, treatment, and efficacy data. Dataset NCT00093470-D2 contains toxicity data reported on study. Dataset NCT00093470-D3 contains toxicity data reported during the first three cycles of treatment or the first three months post registration. |
NCT01802333
Clinical Trial Information
Trial Number: NCT01802333 (ClinicalTrials.gov)
Disease Type:
- Hematopoietic Neoplasm/Leukemia - Acute Myeloid Leukemia
Trial Title:
A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) Versus IA with Vorinostat (NSC-701852) (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Study ID:
S1203
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
NCT02339740
Clinical Trial Information
Trial Number: NCT02339740 (ClinicalTrials.gov)
Disease Type:
- Hematopoietic Neoplasm/Leukemia - Acute Myeloid Leukemia
Trial Title:
A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid
Study ID:
AAML1331
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT02339740-D2 | NCT02339740-D2: There are 2 datasets associated with the PMID 34762093: NCT02339740-D1 through NCT02339740-D2. This dataset, NCT02339740-D2, is an adverse event level dataset (single row per adverse event, period, and patient) containing information of the adverse events of interest by period in the AAML1331 clinical trial. Data for this publication’s historical control, AAML0631, can be found in NCT00866918-D1 and NCT00866918-D2. |
| NCT02339740-D1 | NCT02339740-D1: There are 2 datasets associated with the PMID 34762093: NCT02339740-D1 through NCT02339740-D2. This dataset, NCT02339740-D1 containing patient characteristics, laboratory findings, and outcome for eligible Acute Promyelocytic Leukemia in children enrolled on the AAML1331 clinical trial. Data for this publication’s historical control, AAML0631, can be found in NCT00866918-D1 and NCT00866918-D2. |
NCT02642965
Clinical Trial Information
Trial Number: NCT02642965 (ClinicalTrials.gov)
Disease Type:
- Hematopoietic Neoplasm/Leukemia - Acute Myeloid Leukemia
Trial Title:
A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML)
Study ID:
AAML1421
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT02642965-D1 | NCT02642965-D1 Dataset There is 1 dataset associated with PMID 32401633, NCT02642965-D1. The NCT02642965-D1 dataset is a patient level dataset (single row per patient) containing patient characteristics, response, toxicity, and outcome for eligible pediatric acute myeloid leukemia (AML) patients enrolled on the AAML1421 clinical trial. |
NCT02521493
Clinical Trial Information
Trial Number: NCT02521493 (ClinicalTrials.gov)
Disease Type:
- Hematopoietic Neoplasm/Leukemia - Acute Myeloid Leukemia
Trial Title:
Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Study ID:
AAML1531
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT02521493-D2 | NCT02521493-D2 Dataset There are 2 datasets associated with PMID 34320162, NCT02521493-D1 through NCT02521493-D2. The NCT02521493-D2 dataset is an adverse event level dataset (single row per adverse event, period, and patient) containing information of the micro-organisms associated with adverse events by period in the AAML1531 clinical trial. |
| NCT02521493-D1 | NCT02521493-D1 Dataset There are 2 datasets associated with PMID 34320162, NCT02521493-D1 through NCT02521493-D2. The NCT02521493-D1 dataset is a patient level dataset (single row per patient) containing patient characteristics, laboratory findings, and outcome for eligible myeloid leukemia in children with Down syndrome (ML-DS) enrolled on the AAML1531 clinical trial. |
NCT01307579
Clinical Trial Information
Trial Number: NCT01307579 (ClinicalTrials.gov)
Disease Type:
- Hematopoietic Neoplasm/Leukemia - Acute Myeloid Leukemia
Trial Title:
A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
Study ID:
ACCL0933
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT01307579-D4 | There are four data submissions associated with PMID 31688884: NCT01307579-D1 through -D4. This dataset, NCT01307579-D4, provides adverse events (grade 4-5) during the infection observation period (Appendix eTable 3). Data limited to all evaluable patients with adverse events (N=77). The number of rows per patient is dependent on number of adverse events submitted. |
| NCT01307579-D3 | There are four data submissions associated with PMID 31688884: NCT01307579-D1 through -D4. This dataset, NCT01307579-D3, provides characteristics by Reporting Period (i.e. Cycle) (Appendix eTable 2). Data limited to all evaluable patients (N=508). The number of rows per patient is dependent on number of cycles submitted. |
| NCT01307579-D2 | There are four data submissions associated with PMID 31688884: NCT01307579-D1 through -D4. This dataset, NCT01307579-D2, provides the information for baseline characteristics and all primary, secondary and post-hoc analyses as reported in the manuscript (Tables 1-3 and Appendix eTable 1). Data provided for all eligible patients (N=510) but the analysis is limited to all evaluable patients (N=508, ineval≠1). There is one row per patient. |
| NCT01307579-D1 | There are four data submissions associated with PMID 31688884: NCT01307579-D1 through -D4. This dataset, NCT01307579-D1, provides the information for the consort diagram (Figure 1). Data provided on all enrolled patients (N=517). There is one row per patient. |
NCT01371981
Clinical Trial Information
Trial Number: NCT01371981 (ClinicalTrials.gov)
Disease Type:
- Hematopoietic Neoplasm/Leukemia - Acute Myeloid Leukemia
Trial Title:
A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD
Study ID:
AAML1031
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT01371981-D4 | NCT01371981 – D4 Dataset As of April 2020, there is one dataset associated with this publication (PMID 32029509). The D4 dataset is a patient level dataset which contains patient characteristics, consort diagram classifications, toxicity and outcome analyses in the manuscript for eligible pediatric acute myeloid leukemia (AML) patients enrolled on the AAML1031 clinical trial. |
NCT00372593
Clinical Trial Information
Trial Number: NCT00372593 (ClinicalTrials.gov)
Disease Type:
- Hematopoietic Neoplasm/Leukemia - Acute Myeloid Leukemia
Trial Title:
A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults
Study ID:
AAML0531
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT00372593-D3 | As of November 2019, there is one dataset associated with this publication (PMID 31113932). The D3 dataset is a patient level dataset which contains patient characteristics, genotypes for the SNP of interest, cytogenetic mutation, and outcome analyses for eligible pediatric acute myeloid leukemia (AML) patients enrolled on the AAML0531 clinical trial. |
Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®